Background {#Sec1}
==========

Ebola virus disease (EVD) and Marburg virus disease (MVD) are caused by filoviruses in the family *Filoviridae* and are both associated with high case fatality rates (CFR). The World Health organization (WHO) reports that the CFR of EVD ranges from 25.0 to 90.0% while that of MVD ranges from 24.0 to 88.0% \[[@CR1]\]. In the early phases of a major Ebola outbreak in West Africa, CFR was reported to be 70.8% \[[@CR2]\]. The CFR of EVD seems to be species dependent with *Ebola Zaire* and *Ebola Sudan* species being most pathogenic (with a reported CFR of 100%), while *Ebola Bundibugyo* appears to have a lower CFR at 34% \[[@CR3]\]. A recent study by Lefebvre *et al.* that used data from WHO database estimated the CFR of EVD to be 65.4% irrespective of the Ebola virus species \[[@CR4]\]. A few studies have tried to pool the CFR of EVD and MVD, but did not use the meta-analysis approach \[[@CR5]\].

Although EVD is known to be very severe, there are some species of Ebola virus that cause less serious disease. For example, *Taï Forest ebolavirus,* formerly known as *Côte d'Ivoire ebolavirus*, has not been associated with any fatality and the only case ever reported recovered from the disease \[[@CR6]\]. While there have been some reports of EVD being associated with a CFR of 100%, this CFR is attributed to only a single case fatality that did not result into transmission of the virus to other individuals \[[@CR7], [@CR8]\]. It seems that CFR differs from species to species, however, both *Ebola Sudan* and *Ebola Zaire* have shown a CFR of 100% \[[@CR1]\]. Also, the CFR of the MVD outbreak that occurred in Uganda in 2014 was reported to be 100%, but again only one person was diagnosed and died from the disease \[[@CR9]\]. The largest MVD outbreak was in Angola in 2004 with CFR of 90% \[[@CR10]\] and in Democratic Republic of Congo (DRC) in 1998 with CFR of 83% \[[@CR11]\].

There is evidence that a substantial proportion of infected humans in Central Africa seem to recover without being detected by the health care system, and apparently healthy individuals have been found to be seropositive for Ebola and Marburg viruses \[[@CR12]--[@CR15]\]. Furthermore, Marburg virus has been found in apparently healthy cave-dwelling fruit bats of species *rousettus aegyptiacus,* which are believed to be reservoirs for Marburg virus*,* and responsible for the spill over into human populations \[[@CR16]--[@CR19]\]. Because of the variations in the reported CFR and the presence of seropositive individuals, it is important to determine the severity and prevalence of these viral haemorrhagic fevers. This is important for forecasts and risk analysis especially during outbreaks for epidemic preparedness and response by affected countries. This will help to estimate how many infected people with EVD or MVD are likely to die from the disease during outbreaks. Whereas there are few studies that have estimated CFR of EVD \[[@CR4], [@CR5]\], these did not use a meta-analysis approach and no meta-analysis has been performed on CFR of EVD, MVD, seroprevalence of Ebola and Marburg viruses. Therefore, our aim was to determine the overall weighted estimate (effect size) of the CFR and seroprevalence of EVD and MVD using available published literature on outbreak reports, WHO and CDC databases and population based studies for seroprevalence of filoviruses (Marburg and Ebola viruses). We also explored whether CFR and seroprevalence of these filoviruses differs according to virus species and country.

Methods {#Sec2}
=======

Procedures for systematic reviews and meta-analysis have been developed to summarize scientific evidence from the literature. This work was done following the guidelines published in the PRISMA statement \[[@CR20]\] and MOOSE guidelines for observational studies \[[@CR21]\] as follows.

Literature search strategy {#Sec3}
--------------------------

A detailed literature search was conducted by the authors in PubMed (as well as Medline), Web of Science and Google Scholar until 5^th^ October 2015. In cases where there was no peer-reviewed publication for a known outbreak, data was retrieved from websites of WHO and CDC. The following key words were used; "ebola", "ebolavirus", "viral haemorrhagic fevers", "marburg virus disease", "marburg haemorrhagic fever", "marburg virus outbreak", "ebola virus disease outbreak", "marburg virus", "ebola outbreak", "seroprevalence of ebola virus", "seroprevalence of marburg virus" and "risk factors of viral haemorrhagic fevers". The search included all articles and outbreak reports about EVD and MVD and cross-referencing of primary articles was done to obtain the original articles. Since the number of outbreaks of EVD and MVD are known and few, efforts were made to obtain all information about these outbreaks from WHO and CDC websites and Ministries of health of respective countries.

Study selection criteria {#Sec4}
------------------------

Studies were included in the meta-analysis if they reported the total number of cases and total number of deaths from the outbreak of EVD or MVD. Also studies that were reporting CFR and sero-prevalence in percentages were included. Studies or reports that did not include total number of deaths or cases were excluded as well as studies that did not report original data (Fig. [1](#Fig1){ref-type="fig"}). We also excluded studies that reported outbreaks of Ebola species that are not pathogenic to humans and those species that have not caused mortality in humans. In cases where there were multiple publications, we used the one with the most complete data or the most recent one. In cases where there was controversy on the number of cases and deaths between studies, we cross-referenced with the respective ministries of health, WHO or CDC databases to reconcile these discrepancies. Seroprevalence studies included were only those that were population based and comprised apparently healthy individuals. We excluded articles that reported sero-prevalence during outbreaks or in sick individuals.Fig. 1Flow diagram for search strategy and article selection process from the literature databases

Data extraction {#Sec5}
---------------

LN compiled a list of articles and discrepancies were discussed and resolved by consensus between FM, CK and JL. We used a standardized data extraction form and the following information was extracted for each qualifying study and outbreak report: i) author; ii) Country; iii) number of cases; iv) number of deaths; v) CFR (if reported); vi) month and year of outbreak; vii) year of publication viii) and species involved. For population-based sero-prevalence studies, the following additional information was retrieved: i) sample size and ii) number of seropositive samples.

Statistical analysis {#Sec6}
--------------------

Data were collected in a Microsoft Excel® spreadsheet and outcome measures were calculated. CFR was calculated as number of deaths divided by reported cases whereas seroprevalence was calculated as number of individuals seropositive divided by total sample size in each study. Our effect size (ES), the principal summary measure, was the proportion represented by CFR and seroprevalence. We used the newly developed *metaprop* command \[[@CR22]\] for performing meta-analysis of binomial data in STATA (StataCorp, College Station, TX, USA). The *metaprop* command was preferred to *metan* command because it implements procedures that are specific to binomial data and is appropriate for dealing with proportions close to or at the margins and also uses the Freeman-Tukey double arcsine transformations to stabilize the variances \[[@CR22]\]. The meta-analysis of CFR was stratified by country and species where possible.

The following parameters were estimated: Cochran's Q indicating differences in true ESs, an estimate of the true variance of ESs between studies (our estimate of τ^2^) and Higgins I^2^ which is an estimate of what proportion of the observed variance that reflects real differences in ES. If I^2^ is close to 0, then almost all the observed variation is spurious, and there is nothing to explain. If I^2^ is large, then reasons for the observed variance should be evaluated \[[@CR23], [@CR24]\]. Sensitivity analysis was done by excluding studies that reported very few numbers or zero deaths or no seropositives. A meta-regression procedure was done to assess if factors such as species, country, year and month of outbreak influence CFR of both EVD and MVD using the traditional logit-transformation: Logit (prevalence) = ln \[prevalence/ (1 − prevalence)\] Variance (logit) =1/ (np) +1/\[n (1 − p)\] \[[@CR25]\]. The Begg's and Egger's tests were used in combination with a funnel plot to assess potential publication bias and visualised using funnel plots \[[@CR24], [@CR26]\].

Results {#Sec7}
=======

Literature search result {#Sec8}
------------------------

Results from the literature search are illustrated in Fig. [1](#Fig1){ref-type="fig"}. The literature search yielded 7551 articles. Of these, 4898 were excluded as duplicates. After reviewing the titles and the abstract, only 153 articles were retrieved for detailed evaluation. After full evaluation of retrieved publications, 72 articles were included in this study. Of those included in the study, 23 reported outbreaks of EVD (Table [1](#Tab1){ref-type="table"}) \[[@CR3], [@CR8], [@CR27]--[@CR41], [@CR7], [@CR42], [@CR43]\], 12 reported outbreaks of MVD (Table [2](#Tab2){ref-type="table"}) \[[@CR10], [@CR11], [@CR42], [@CR44]--[@CR51]\], 26 reported sero-prevalence of Ebola virus (Table [3](#Tab3){ref-type="table"}) \[[@CR8], [@CR12]--[@CR14], [@CR28], [@CR31], [@CR52]--[@CR54], [@CR29], [@CR55]--[@CR70]\] and 11 reported sero-prevalence of Marburg virus (Table [4](#Tab4){ref-type="table"}) \[[@CR14], [@CR15], [@CR57], [@CR61]--[@CR64], [@CR67], [@CR71]--[@CR73]\]. Most of the sero-prevalence studies reported both Marburg and Ebola viruses.Table 1Summary of the studies included in a systematic review and meta-analysis describing case fatality rate for Ebola virus disease in AfricaAuthor and Year of PublicationDeathsCasesCountryYear and month of outbreakWHO International Study Team, 1978 \[[@CR27]\]151284South Sudan1976, June--NovemberInternational Commission, 1978 \[[@CR28]\]280318DRC1976, Sept--OctHeymann et al., 1980 \[[@CR8]\]11DRC1977, JuneBaron et al., 1983 \[[@CR29]\]2234South Sudan1979, June--OctAmblard et al., 1997 \[[@CR30]\]3049Gabon1994, NovemberKhan et al., 1999 \[[@CR32]\]255315DRC1995, MayGeorges et al., 1999 \[[@CR31]\]2131Gabon1996, MayMilleliri et al., 2004 \[[@CR34]\]4560Gabon1996, MayOkware et al., 2002 \[[@CR33]\]224425Uganda2000, OctoberNkoghe et al., 2005 \[[@CR36]\]97124Gabon2000, DecemberRouquet et al. (2005) \[[@CR37]\]128143ROC2003, DecemberBoumandouki et al., 2005 \[[@CR35]\]2935ROC2003, Oct--DecOnyango et al., 2007 \[[@CR38]\]717South Sudan2004, April--JuneNkoghe et al., 2011 \[[@CR41]\]1012ROC2005, April--MayLeroy et al., 2009 \[[@CR39]\]186264DRC2007, May and NovemberWamala et al., 2010 \[[@CR3]\]39116Uganda2007, AugustGrard et al., 2011 \[[@CR40]\]1532DRC2008, JanShoemaker et al., 2012 \[[@CR7]\]11Uganda2011, MayAlbariño et al., 2013 \[[@CR42]\]411Uganda2012, JulyAlbariño et al., 2013 \[[@CR42]\]36Uganda2012, NovAlbariño et al., 2013 \[[@CR42]\]1336DRC2012, AugustMaganga et al., 2014 \[[@CR43]\]4969DRC2014, JulyWHO, 2016 \[[@CR79], [@CR90]\]1132328646West AfricaMarch, 2014*DRC* Democratic Republic of Congo, *ROC* Republic of Congo Table 2Summary of studies included in a systematic review and meta-analysis describing case fatality rate for Marburg virus from searched literature globallyAuthor and Year of PublicationDeathsCasesCountryYear & Month of outbreakSiegert, 1972 \[[@CR44], [@CR45]\]731Germany and Yugoslavia1967, AugustGear et al., 1975 \[[@CR91]\]13Johannesburg, South Africa1975, FebruarySmith et al., 1982 \[[@CR92]\]12Kenya1980, JanuaryJohnson et al., 1996 \[[@CR49]\]11Kenya1987, AugustNikiforov et al., 1994 \[[@CR48]\]11Russia1990Bausch et al., 2006 \[[@CR11]\]128154DRC1998, OctoberTowner et al., 2006 \[[@CR10]\]227252Angola2004, OctoberAdjemian et al., 2011 \[[@CR51]\]14Uganda2007, JuneCenters for Disease & Prevention, 2009 \[[@CR50]\]01USA from Uganda2008, JanuaryTimen et al., 2009 \[[@CR93]\]11Netherlands from Uganda2008, JulyAlbarino et al., 2013 \[[@CR42], [@CR94]\]415Uganda2012, OctoberWHO, 2015 \[[@CR95]\]11Uganda2014, October*DRC* Democratic Republic of Congo Table 3Summary of studies included in a systematic review and meta-analysis describing sero-prevalence of Ebola virus from literatureAuthor and Year of PublicationSample sizeSeropositiveCountryVan der Groen and Pattyn 1979 \[[@CR96]\]25143DRCSaluzzo, Gonzalez et al. 1980 \[[@CR97]\]49917CARBouree & Bergmann, 1983 \[[@CR55]\]1517147CameroonJohnson et al., 1983 \[[@CR56]\]7418KenyaVan der Waals, Pomeroy et al. 1986 \[[@CR57]\]22530LiberiaMeunier et al., 1987 \[[@CR58]\]1528319CARPaix et al., 1988 \[[@CR59]\]3754CameroonTomori, Fabiyi et al. 1988 \[[@CR60]\]1,67730NigeriaGonzalez et al., 1989 \[[@CR72]\]5070629Central AfricaMathiot, Fontenille et al. 1989 \[[@CR61]\]38117MadagascarJohnson, Gonzalez et al.1993a \[[@CR63]\]42775CARJohnson, Gonzalez et al. 1993b \[[@CR64]\]4295914CARBusico et al., 1999 \[[@CR66]\]57524DRCNakounne, Selekon et al. 2000 \[[@CR67]\]1762104CARHeffernan et al., 2005 \[[@CR69]\]97914GabonAllela et al., 2005 \[[@CR68]\]43964GabonLahm, Kombila et al. 2007 \[[@CR70]\]114714GabonBecquart et al., 2010 \[[@CR12]\]4349665DRCHeymann et al., 1980 \[[@CR8]\]109679DRCBurke et al., 1978 \[[@CR28]\]98438DRCBaron et al., 1983 \[[@CR29]\]10623SudanGeorges et al., 1999 \[[@CR31]\]44158GabonBecker, Feldmann et al. 1992 \[[@CR62]\]128811GermanyGonzalez, Nakoune et al. 2000 \[[@CR14]\]133171CARBertherat, Renaut et al. 1999 \[[@CR65]\]23624GabonNkoghe, Padilla et al. 2011 \[[@CR13]\]4349667DRC*DRC* Democratic Republic of Congo, *ROC* Republic of Congo, *CAR* Central African Republic Table 4Summary of studies included in a systematic review and meta-analysis describing sero-prevalence of Marburg disease from published literatureAuthor and Year of PublicationSample sizeSeropositiveCountryVan der Waals, Pomeroy et al. 1986 \[[@CR57]\]2253LiberiaGonzalez, Josse et al. 1989 \[[@CR72]\]507020Central African countriesJohnson, Ocheng et al. 1983 \[[@CR71]\]18998KenyaMathiot, Fontenille et al. 1989) \[[@CR61]\]3840MadagascarBecker, Feldmann et al. 1992 \[[@CR62]\]128834GermanyJohnson, Gonzalez et al. 199a \[[@CR63]\]4275CARJohnson, Gonzalez et al. 1993b \[[@CR64]\]4295137CARGonzalez, Nakoune et al. 2000 \[[@CR14]\]134033CARNakounne, Selekon et al. 2000 \[[@CR67]\]176235CARBausch, Borchert et al. 2003 \[[@CR15]\]91215DRCBorchert, Mulangu et al. 2006 \[[@CR73]\]3000DRC*DRC* Democratic Republic of Congo, *CAR* Central African Republic

Two more outbreaks have occurred without human mortalities namely Ebola Reston \[[@CR74], [@CR75]\] and another caused by *Taï* Forest virus \[[@CR6]\]. *Zaire ebolavirus* species was responsible for most of the outbreaks with 14/23 (60.9%) \[[@CR8], [@CR28], [@CR30]--[@CR32], [@CR34]--[@CR36], [@CR39], [@CR40], [@CR41], [@CR37], [@CR76]\] followed by *Sudan ebolavirus* with 30.3% (7/23) outbreaks \[[@CR27], [@CR29], [@CR38], [@CR7], [@CR42], [@CR77]\] and lastly *Bundibugyo ebolavirus* 8.7% (2/23) \[[@CR3], [@CR42]\]. Most articles reported DRC (7/23) \[[@CR8], [@CR28], [@CR32], [@CR39], [@CR40], [@CR42], [@CR76]\] and Uganda (5/23) \[[@CR3], [@CR33], [@CR7], [@CR42]\] as countries most affected by EVD outbreaks. Other countries reported include Gabon (4/23) \[[@CR31], [@CR34], [@CR36], [@CR78]\], Republic of Congo (3/23) \[[@CR35], [@CR37], [@CR41]\], South Sudan (3/23) \[[@CR27], [@CR29], [@CR38]\] and multiple countries in West Africa associated with the recent single outbreak \[[@CR79]--[@CR82]\]. Interestingly, most of the EVD outbreaks occurred during months of May, June and July and no outbreaks were reported in the month of February.

Meta-analysis and meta-regression of CFR and seroprevalence of EVD {#Sec9}
------------------------------------------------------------------

The weighted CFR of EVD from 23 outbreaks was 65% (95% CI: 54--76%) (Fig. [2](#Fig2){ref-type="fig"}). There was a substantial between-study variance indicating heterogeneity in the overall CFR of EVD, I^2^ = 97.98%. On stratification by Ebola virus species, the CFR for *Sudan ebolavirus* was 53%, *Bundibugyo ebolavirus* was 34%, whereas that of *Zaire ebolavirus* was 75%. From the meta-regression, the CFR for *Zaire ebolavirus* was higher compared to other Ebola species (=0.006, Coefficient = 0.19, 95% CI = 0.063 - 0.588). In sub-analysis analysis by country, the highest CFR for EVD was observed in Republic of Congo (89.0%, 84.0--93.0%) whereas the lowest was found in Uganda (43.0%, 27.0--61.0%) (Fig. [3](#Fig3){ref-type="fig"}). However, the large West African EVD outbreak that affected multiple countries had an even lower CFR at 40% (39--40%). The pooled ES for Ebola virus seroprevalence was 8% \[5--11%) with substantial between-study variance (I^2^ = 98.7%) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 2Forest plot showing stratified meta-analysis of CFR of Ebola Virus Disease by virus species estimated by the random effects model (I^2^ = Higgins statistic, ES = Effect size, CI = Confidence Interval) Fig. 3Forest plot showing stratified meta-analysis of CFR of Ebola virus disease by country estimated by the random effects model (I^2^ = Higgins statistic, ES = Effect size, CI = Confidence Interval, DRC = Democratic Republic of Congo, ROC = Republic of Congo) Fig. 4Forest plot for the meta-analysis of sero-prevalence studies of Ebola virus (I^2^ = Higgins statistic, ES = Effect size, CI = Confidence Interval)

Meta-analysis and meta-regression of CFR and seroprevalence of MVD {#Sec10}
------------------------------------------------------------------

The MVD CFR was lower than that of EVD (61%) (Fig. [5](#Fig5){ref-type="fig"}). There was no significant difference between CFR of MVD and different variables in the meta-regression model (*P* = 0.637). The pooled seroprevalence of Marburg virus was lower than that of Ebola virus at 1.2% (0.5--2%) (Fig. [6](#Fig6){ref-type="fig"}).Fig. 5Forest plot for a meta-analysis of CFR of Marburg virus disease estimated using a random effects model (I^2^ = Higgins statistic, ES = Effect size, CI = Confidence Interval) Fig. 6Meta-analysis of seroprevalence of Marburg virus estimated using a random effects model (I^2^ = Higgins statistic, ES = Effect size, CI = Confidence Interval)

Publication bias {#Sec11}
----------------

In the funnel plots, asymmetry was evident which gives rise to suspected publication bias (Fig. [7](#Fig7){ref-type="fig"}). Egger's test was significant for studies reporting CFR and seroprevalence of EVD and MVD (*P* = 0.001, *P* \< 0.001, *p* = 0.032, and 0.046 respectively). However, the Begg's bias test was not significant for studies reporting CFR of EVD and MVD (*p* = 0.091 and *p* = 0.293 respectively), seroprevalence of MVD (*p* = 0.95), but was significant for studies reporting seroprevalence of EVD (*p* = 0.007).Fig. 7Funnel plots assessing publication bias in studies reporting case fatality rate and seroprevalence of Ebola virus disease and Marburg virus disease. **a** Funnel plot of the point estimates of the logit CFR of EVD, **b** Funnel plot of the point estimates of the logit prevalence of EVD, **c** Funnel plot of the point estimates of the logit CFR of MVD, **d** Funnel plot of the point estimates of the logit prevalence of MVD

Discussion {#Sec12}
==========

Our findings show that the overall pooled CFR of EVD of 65% was lower than the previously reported CFR of 90% \[[@CR83]\]. This indicates, despite substantial heterogeneity, that more than half of the individuals who contract EVD are more likely to die. Although this CFR appears to be high, it is lower than the exaggerated figure of 90%. This high CFR tends to cause fear and panic in the general public and hence interferes with response mechanisms \[[@CR84]\]. The CFR in our study is similar to that reported by Lefebvre *et al.* \[[@CR4]\], who reported a CFR of 65% in a study done using WHO database on EVD outbreaks. Although there have been cases of EVD and MVD with 100% CFR \[[@CR8], [@CR7]\], these were isolated single cases that should not be generalized by scientific community to consider Ebola and Marburg viruses as highly virulent diseases with CFR of up to 90%. There have been reports with a higher CFR than our maximum of 76% \[[@CR28], [@CR35], [@CR37], [@CR41]\], but these either happened long time ago \[[@CR28]\] where there was little knowledge about the disease or happened in very remote places where health care delivery systems are not robust.

The high CFR of EVD in Republic of Congo (89%) compared to Uganda (43%) may be due to partly, differences in health care system and response mechanisms to outbreaks, but also the severity of the species of Ebola virus involved. For example, Uganda has developed a robust surveillance system for detecting these viral haemorrhagic fevers and epidemic response is started within hours of a positive diagnosis at a CDC supported laboratory in the country \[[@CR85]\]. The well-established disease surveillance system and organised health care delivery in endemic areas might explain the lower CFR for EVD observed in Uganda. But it is also important to note that Uganda has been affected by the less pathogenic species of Ebola virus (*Sudan ebolavirus* and *Bundibugyo ebolavirus*) as compared to DRC and West African countries that have experienced *Zaire ebolavirus* Also, it is important to look at the denominators and numerators when interpreting the CFR. In this analysis, we see that CFR of EVD in a large outbreak in West Africa that affected multiple countries is at CFR of 40% using WHO data, but this alone would be misleading if the real numbers of deaths and cases were not looked at. As of 30^th^ March 2016, there were 11323 deaths and 28646 cases due to EVD from all countries affected by that outbreak.

Another significant finding of our study was the variation in the severity and CFR among the pathogenic species of Ebola virus. Zaire *ebolavirus* (CFR, 75%) was found to be the most severe followed by *Sudan ebolavirus* (CFR, 53%), while *Bundibugyo ebolavirius* (CFR, 34%) was the least severe species. This finding is supported by McCormick *et al.*, who described differences in severity and filovirus dynamics \[[@CR86], [@CR87]\]. The reasons for severity of *Zaire ebolavirus* are unclear, thus there is a need for further research to determine whether genetic differences are responsible for the variation in pathogenesis of these species. There was also heterogeneity within *Zaire ebolavirus* outbreaks (P \< 0.001) meaning that these outbreaks, although caused by the same species are not always similar. The heterogeneity could further be explained by differences in outbreak investigation designs or approaches, location of the outbreak and data collection methods. This is further supported by the strains that have been found within Ebola Zaire species \[[@CR40]\]. There was less heterogeneity in outbreak reports for *Bundibugyo ebolavirus* and *Sudan ebolavirus* probably due to few outbreaks that have been caused by these species. However, the meta-regression did not show any influence on CFR of EVD by country of outbreak (*p* = 0.249). This is probably due to low power given the few number of outbreaks that we have had globally.

With the *Metaprop* command for meta-analysis of marginal proportions \[[@CR22]\], it was possible to estimate the 95% confidence intervals for MVD as 61% (32--88%). The CI was very wide because of the few outbreaks and the number of cases involved in MVD outbreaks as compared to EVD outbreaks. Dropping studies with 100% or 0% CFR for MVD, the CFR reduced from 61 to 53%. With few outbreaks of Marburg virus in different countries, there is a high variation that would impact the estimation of CFR for MVD, but this was not significant from the meta-regression (*p* = 0.913).

We found that apparently healthy individuals in central African countries, that are endemic for viral haemorrhagic fevers, had a 5 and 1% chance of having antibodies against Ebola and Marburg viruses, respectively. This finding suggests that some individuals who get infected with filoviruses make a full recovery without severe complications and being documented by healthcare systems. Although the sero-prevalence is low, it is important that these seropositive individuals are detected early enough because of greater mortality and socio-economic implications associated with these infections. Because serological tests have been reported to have low specificity and there is a lot of cross-reactivity of filoviruses with other viral haemorrhagic fevers \[[@CR88]\], this finding should be interpreted with caution. It is important that specific and more accurate tests are developed to accurately measure antibody response against filoviruses and progress in this direction has been made due to the recently approved rapid diagnostic test for Ebola virus by WHO \[[@CR89]\].

The limitation of our ES estimates was the heterogeneity that was observed between studies. Efforts to identify sources of heterogeneity were made, and many unmeasured factors could have influenced CFR during outbreaks. These reports had data that were collected using different methods and hence combining them to produce one effect was likely to produce high heterogeneity. Sensitivity analysis by dropping single cases with 100% mortality did not have substantial impact on the result. Funnel plots and Beggs tests suggested that publication bias might have been present, meaning that studies with negative results about Ebola and Marburg viruses are less likely to be published hence affecting the estimate of seroprevalence and CFR for EVD and MVD.

The fact that laboratory tests for Ebola and Marburg viruses are expensive, used only in specific laboratories and that serological tests are not specific might influence the publication of studies done with these tests.

Conclusions {#Sec13}
===========

The CFR for Ebola and Marburg viruses is still moderately high but not as high as has been reported in the media and other publications. The CFR of EVD and MVD is higher in countries with poor disease surveillance systems. This calls for an improved surveillance system that will enhance early detection and response to these filovirus outbreaks to avoid a pandemic. The presence of seropositive individuals in apparently health populations indicate that cases go undetected by the health care system in affected countries; further calling for robust surveillance for Ebola and Marburg viruses.
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